Datopotamab Deruxtecan

Phase 3

Daiichi Sankyo (DSKYF)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Metastatic Non Small Cell Lung Cancer

IOVALN-145

Phase 2

View Full Landscape

Drug Information

Target Indication

Metastatic Non Small Cell Lung Cancer

Clinical Trial

NCT05215340

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMAPending

Datopotamab deruxtecan Daiichi Sankyo

Treatment of adult patients with locally advanced or metastatic non squamous non-small cell lung cancer (NSCLC)

View on EMA

EMA4/4/2025

Datroway

Breast cancer Datroway as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

DSKYF

Daiichi Sankyo

Healthcare•North America•NASDAQ

Related Pipeline

T-DXdPhase 3

Advanced Cancer

QuizartinibPhase 3

Leukemia